Acceleron Reports First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acceleron Pharma (XLRN) Tops Q1 EPS by 4c, Revenues Miss
May 6, 2021 4:04 PM EDTAcceleron Pharma (NASDAQ: XLRN) reported Q1 EPS of ($0.77), $0.04 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $24.76 million versus the consensus estimate of $28.89 million.
Acceleron made significant operational progress during the first quarter, said Habib Dable, President and Chief Executive Officer of Acceleron. With the STELLAR Phase 3 trial already enrolling patients, we expect to initiate multiple mid- and late-stage clinical... More
